To evaluate drug survival of secukinumab in a daily practice setting, we retrospectively
evaluated all psoriatic patients starting secukinumab during January 2016-February 2017 at …

Introduction There is limited and conflicting evidence over the real-world drug survival of
secukinumab (SEC) in patients with psoriasis, especially in the long term. Our objective was …

Background: Little is known about the treatment outcomes of secukinumab in clinical
practice, which differ from those in clinical trials. The effectiveness of biologics may differ in …

Background There are limited data regarding the long‐term continuation with biological
therapy for patients with psoriasis. In particular, the reasons for secukinumab discontinuation …

Background Long-term real-life data on secukinumab use in psoriasis are limited. Objectives
Determine the long-term effectiveness of secukinumab in moderate-to-severe psoriasis in …

Background: Long term data on the real-life use of secukinumab are scant. The aim of this
study was to investigate the real-life effectiveness, safety and treatment persistence of …

Background Psoriasis is a chronic systemic disease that requires long‐term management.
Despite data on follow‐up studies going back 5 years, little is known about the condition's …

Objective: To examine the real-world effectiveness of secukinumab with regard to clinical
and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in …

Background Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, has
demonstrated efficacy and safety in patients with moderate‐to‐severe psoriasis. Trial …

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug
failure also with very effective drugs (ie, secukinumab) and, consequently, dermatologists …